Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Fineline Cube Feb 10, 2026
Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Fineline Cube Feb 10, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Fineline Cube Feb 10, 2026
Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Deals

Inkon Life Technology Partners with United Imaging to Establish Advanced Medical Centers and Digital Platform

Fineline Cube Jun 24, 2024

Inkon Life Technology Co., Ltd. (SHE: 300143), a Shenzhen-based service provider specializing in stereotactic radiotherapy...

Company Deals

METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery

Fineline Cube Jun 24, 2024

METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in...

Company Drug

Qilu Pharmaceutical’s Generic Version of Vyndaqel Receives NMPA Marketing Approval

Fineline Cube Jun 21, 2024

The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...

Company Deals Medical Device

Jiangsu Yuyue Medical Teams Up with China Unicom for Digital Healthcare Innovation

Fineline Cube Jun 21, 2024

Shanghai-based Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223) has announced a strategic partnership with China...

Company Deals

Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial

Fineline Cube Jun 21, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Deals Hospital

Shineco Inc. Acquires 80% Stake in ‘Internet+Medical Care’ Platform Meitong Tech for USD 20 Million

Fineline Cube Jun 21, 2024

Shineco Inc. (NASDAQ: SISI), a U.S.-based company, has signed an investment agreement with Beijing Dongfang...

Company Drug

Zhangzhou Pien Tze Huang’s PZH2113 Receives NMPA Clinical Trial Approval for Lymphoma Treatment

Fineline Cube Jun 21, 2024

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (SHA: 600436), a renowned traditional Chinese medicine (TCM)...

Company Drug

Tonghua Dongbao Pharmaceuticals’ THDBH120 Receives NMPA Approval for Phase II Clinical Trial

Fineline Cube Jun 21, 2024

Tonghua Dongbao Pharmaceuticals (SHA: 600867), based in China, has announced that the National Medical Products...

Company Deals

DK Medical Technology Secures ‘Hundreds of Millions’ in Series E Financing for Expansion

Fineline Cube Jun 21, 2024

DK Medical Technology Co. Ltd., a Suzhou-based developer of vascular intervention balloon products, has reportedly...

Company Deals

Shanghai Fudan-Zhangjiang and Hanhui Pharmaceutical End Marketing Deal for Libaoduo

Fineline Cube Jun 21, 2024

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a Chinese biopharmaceutical company, has reached...

Company Drug

Luye Pharma’s Once-Weekly Parkinson’s Disease Treatment Receives NMPA Approval

Fineline Cube Jun 21, 2024

Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from the...

Company Drug

Fudan-Zhangjiang Bio-Pharmaceutical Advances Aminolevulinic Acid Study for Glioma Visualization

Fineline Cube Jun 21, 2024

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the first subject...

Company Deals

Novartis Moves Toward Full Ownership of MorphoSys with Shareholder Squeeze-Out

Fineline Cube Jun 21, 2024

Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, is proceeding to fully acquire MorphoSys AG...

Policy / Regulatory

China Expands Controlled Substances Catalogue to Include Three Additional Substances

Fineline Cube Jun 20, 2024

The Ministry of Public Security, National Health Commission, and National Medical Products Administration in China...

Company Drug

Dizal Pharmaceutical’s Golidocitinib Wins NMPA Approval for Relapsed/Refractory PTCL

Fineline Cube Jun 20, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China established in 2017, has...

Company Deals

Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million

Fineline Cube Jun 20, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of...

Company

Jiuzhou Pharmaceutical Shuts Down Two Subsidiaries to Streamline Operations

Fineline Cube Jun 20, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a pharmaceutical company based in China, has announced...

Company Drug

Keymed Biosciences’ CM313 Shows Promise in Treating Immune Thrombocytopenia, NEJM Study Says

Fineline Cube Jun 20, 2024

Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has published results from...

Company Deals

Xencor Reclaims Rights to Plamotamab After Janssen Halts Development

Fineline Cube Jun 20, 2024

Xencor Inc. (NASDAQ: XNCR), a U.S.-based biotechnology company, has announced that Johnson & Johnson (J&J,...

Company Drug

AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio

Fineline Cube Jun 20, 2024

AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...

Posts pagination

1 … 298 299 300 … 622

Recent updates

  • Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million
  • Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med
  • Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage
  • Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology
  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Zhongsheng Pharma Licenses RAY1225 GLP-1/GIP Dual Agonist to Qilu Pharma for $144 Million

Company Deals

Kintor Pharma Signs Exclusive China Distribution Deal for Anti-Hair Loss Foam with Dekai Med

Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Company Deals

Bao Pharma Partners with Shanghai RAAS to Develop Subcutaneous Blood Products Using Hyaluronidase Technology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.